Guidelines for hormone treatment of women in the menopausal transition and beyond

Climacteric

Volumn 7, Issue 4, 2004, Pages 333-337

  Naftolin, F ^a   Schneider, H P G ^a   Sturdee, D W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

AGING; ALCOHOL ABUSE; BREAST CANCER; CANCER INVASION; CANCER RISK; CLINICAL TRIAL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; HEART PROTECTION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; LIFESTYLE; LUNG EMBOLISM; MATERNAL AGE; MENOPAUSE; PATIENT EDUCATION; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SMOKING CESSATION; STROKE; THROMBOEMBOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS;

EID: 10944237838     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130400014615     Document Type: Review

References (25)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal resuits from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33
2. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-3 4
3. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. J Am Med Assoc 2003;289:3243-53
4. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-27
5. Sturdee DW, MacLennan A. HT or HRT, that is the question? Climacteric 2003;6:1
6. Gambacciani M, Genazzani AR. The missing R. Gynecol Endocrinol 2003;17:91-4
7. Kuhl H. Is the elevated breast cancer risk observed in the WHI study an artifact? Climacteric 2004;7:319-22
8. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004;291:1701-12
9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary disease in postmenopausal women. J Am Med Assoc 1998;280:605-13
10. Herrington DM, Reboussin DR, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-9
11. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54
12. Naftolin F, Taylor HS, Karas R. Early initiation of hormone therapy and clinical cardioprotection: the Women's Health Initiative (WHI) could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004;81:1498-1501
13. Shapiro S. Effects of HRT on the risks of breast cancer and cardiovascular disease: the validity of the epidemiological evidence. In Schneider HPG, Naftolin F, eds. Climacteric Medicine - Where Do We Go? Proceedings of the 4th Workshop of the International Menopause Society. London, New York: Parthenon Publishing, 2004:166-74
14. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from two large clinical trials. Arch Intern Med 2004;64:482-4
15. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. J Am Med Assoc 2004;292:1573-80
16. Karas RH, Clarkson TB. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything. Menopausal Med 2003;10:8-12
17. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41
18. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone treatment and mortality. N Engl J Med 1997;336:1769-75
19. Joakimsen O, Bønaa KH, Stensland-Bugge E, Jacobsen BK. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis. J Clin Epidemiol 2000;53:525-30
20. Hu FB, Stampfer MJ, Manson JE, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000;343:530-7
21. Mack WJ, Hameed AB, Xiang M, et al. Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the estrogen in the prevention of atherosclerosis trial. Atherosclerosis 2003;168:91-8
22. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32
23. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. J Am Med Assoc 2002;88:2123-9
24. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary atherosclerosis by 17β-estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7
25. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. J Am Med Assoc 2004;291:2947-58